Clinical trials: Liver and Intrahepatic Bile Duct Carcinoma
Hepatocellular Carcinoma, Liver Cancer
Radioembolization With Yttrium-90 Microspheres for Intermediate or Advanced Hepatocellular Carcinoma
Rationale: Patients diagnosed with hepatocellular carcinoma (HCC) at an intermediate or advanced stage (according to the BCLC classification system) are not amenable of curative treatment.
- Trial name
- NCT00910572
- Testing
- Yttrium-90 microspheres (Therasphere MDS Nordion)
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Esophageal Cancer, Kidney Cancer
GI Organ Tracking Via Balloon Applicators
The hypothesis of this study is that an occlusion balloon catheter placed in the stomach via an oral or nasogastric route will be safe and permit tracking of the stomach during radiation therapy.
- Conditions
- Esophageal Cancer, Kidney Cancer, Larynx Cancer, Liver Cancer
- Trial name
- NCT05471401
- Testing
- Balloon-tipped catheter
- Sponsor
- Washington University School of Medicine
Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma
Inter-Individual Tumor Heterogeneity on 3D-MRE for Predicting Response to Conversion Therapy in Liver Cancer
How to predict which patients with initially unresectable liver cancer are more likely to respond to conversion therapy remains an important unresolved problem in guiding treatment strategy and surgical timing.
- Conditions
- Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT07716345
- Testing
- Three-Dimensional Magnetic Resonance Elastography
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Hepatocellular Carcinoma, Cirrhosis, Liver
Liver Cancer Disparities in American Indian and Alaska Native Persons
We are performing a pilot and feasibility randomized controlled trial (RCT) of HCC screening by US + AFP every 6 months (n=100), the current standard-of-care, versus aMRI + AFP every 6 months (n=100) for 12 months (i.e.
- Conditions
- Hepatocellular Carcinoma, Cirrhosis, Liver, Hepatitis B
- Trial name
- NCT05304234
- Testing
- Ultrasound or abbreviated MRI
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Washington
Liver Cancer, Ototoxicity
Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, II, or III Childhood Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- SIOPEL6 (NCT00652132)
- Testing
- cisplatin, sodium thiosulfate
- Where
- 16 sites in United Kingdom
- Volunteers
- 116 people
- Sponsor
- University of Birmingham
Liver Cancer
vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC
This trial will provide the maximum tolerated dose for radiation therapy for liver tumors and describe the toxicity profile using the vGRID therapy technique.
- Trial name
- vGRID SBRT (NCT05727787)
- Testing
- Stereotactic Body Radiation Treatment
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Kansas Medical Center
BCLC Stage a Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy
This early phase I trial evaluates the use of hypoxia (lack of oxygen) as a measure in determining the outcome of Y90 selective internal radiation therapy in patients with liver cancer that has spread to a limited number of sites…
- Conditions
- BCLC Stage a Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT05250895
- Testing
- 18F-Fluoromisonidazole, Biopsy, Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Emory University
Liver Cancer, Sarcopenia
Effect of Sarcopenia on HCC After Lenvatinib and Anti-PD-1 Treatment
Sarcopenia is associated with the prognosis of HCC and cholangiocarcinoma. But there has been rare study focusing on the effect of sarcopenia on the prognosis of HCC treated with lenvatinib and anti-PD1.
- Trial name
- NCT05443230
- Testing
- gait speed; ct scan; grip strength and chair stand test
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Liver Cancer
Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Using radiolabeled glass beads to kill tumor cells may be effective treatment for liver cancer that cannot…
- Trial name
- NCT00589030
- Testing
- brachytherapy, yttrium Y 90 glass microspheres
- Where
- United States
- Sponsor
- City of Hope Medical Center
Hepatocellular Carcinoma, Liver Cancer
Comparison of Criteria for Liver Transplantation in Hepatocellular Carcinoma
Hepatocellular cancer is the 6th most common seen disease in the world and the 3rd in cancer-related deaths. Liver transplantation is the primary curative treatment of HCC, as it eliminates liver cancer and underlying cirrhosis.
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Advanced Adult Hepatocellular Carcinoma, Cirrhosis, Liver
- Trial name
- NCT04576572
- Where
- Turkey (Türkiye)
- Volunteers
- 424 people
- Sponsor
- Inonu University
Adult Liver Cancer
Accuracy Assessment for Computer-assisted Surgical Interventions of the Liver
Preoperative image-guided data correlates with the actual intraoperative reality. Computer-assisted preoperative planning combined with intraoperative mapping of even very small lesions allows for improved accuracy during…
- Trial name
- CALS (NCT01474694)
- Testing
- Abdominal surgery
- Where
- Switzerland
- Volunteers
- 14 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Liver Diseases, Liver Neoplasm
Impact of a European Training Program for Robotic Liver Surgery (LIVEROBOT)
LIVEROBOT is a collaboration of high-volume liver surgical centers in Europe (≥60 liver resections per year), supported by the European-African Hepato-Pancreato-Biliary Association Education Committee (E-AHPBA), and the European…
- Conditions
- Liver Diseases, Liver Neoplasm, Liver Cancer, Liver Metastases
- Trial name
- LIVEROBOT (NCT05723705)
- Testing
- European Multicentre Training Program for Robotic Liver Surgery
- Volunteers
- 3,600 people
- Sponsor
- Amsterdam UMC, location VUmc
Carcinoma, Hepatocellular
Effect of Enhanced Recovery After Surgery(ERAS) After Liver Resection for Primary Liver Cancer
The purpose of this study is to evaluate Enhanced Recovery After Surgery(ERAS) protocol versus conventional treatment on patients who underwent liver resection for hepatocellular carcinoma(HCC).
- Trial name
- NCT02644603
- Testing
- Enhanced Recovery After Surgery
- Where
- China
- Volunteers
- 214 people
- Sponsor
- Shanghai Zhongshan Hospital
Liver Cancer, Liver Metastases
DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
The DRAGON registry aims to collect data on combined portal and hepatic vein embolization (PVE/HVE) for liver tumors, a technique expected to enhance liver regeneration compared to standard PVE.
- Trial name
- NCT07717437
- Where
- 31 sites in United States, Australia and 11 more
- Volunteers
- 350 people
- Sponsor
- Maastricht University Medical Center
Hepatocellular Carcinoma (HCC), Treatment Response
Multimodalomics-based Construction of Spatiotemporal Characteristics of Dynamic Liver Cancer Microenvironment to Characterize the Clinical Application of Immune Mechanisms in Liver Cancer
This study aims to explore whether adding an additional MRI sequence to routine liver scans can better characterize the immune microenvironment of liver cancer.
- Trial name
- NCT07838415
- Testing
- time-dependent diffusion MRI and Cest sequence
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Tongji Hospital
Cholangiocarcinoma
The Expression of CD24 "do-not-eat-me" Signal in Cholangiocarcinoma
The investigators found an inverse relationship between CD24 and MiR-122 levels. Then the investigators found that CD24 that goes up with MiR-122 down makes macrophages unable to engulf the tumor cells. All this in mice.
- Trial name
- CD24CCA (NCT06707025)
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Hadassah Medical Organization
Cancer
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499733
- Testing
- cyclophosphamide, Cryoablation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hepatocellular Carcinoma
AFP- L3% and DCP as Tumor Markers in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolisation (TACE)
Hepatocellular carcinoma (HCC) is one of the tumors with an increasing incidence worldwide. Often treatment possibilities are limited and only palliative treatment such as a transarterial chemoembolisation (TACE) is possible.
- Trial name
- NCT01360255
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- University Hospital Freiburg
Hepatocellular Carcinoma, Cholangiocarcinoma, Intrahepatic
Standardized CEUS Algorithms for Diagnosis of HCC - Prospective German Multicenter Study
Aim of this prospective national multicenter study is to improve standardization of contrast-enhanced ultrasound (CEUS) in the non-invasive diagnosis of hepatocellular carcinoma (HCC) in high-risk patients.
- Conditions
- Hepatocellular Carcinoma, Cholangiocarcinoma, Intrahepatic, Liver Cirrhosis, Liver Cancer
- Trial name
- ESCULAP (NCT03405909)
- Testing
- contrast enhanced ultrasound (CEUS), MRI, Histology
- Where
- Germany
- Volunteers
- 517 people
- Sponsor
- University Hospital Erlangen
Breast Cancer, Lung Cancer
Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2
The goal of this clinical trial is to explore feasibility, acceptability, and effectiveness of end-of-life conversation game "Hello" as a tool to help individuals with various solid cancer types (including: breast…
- Conditions
- Breast Cancer, Lung Cancer, Genito-Urinary Cancer, Colorectal Cancer
- Trial name
- NCT06384417
- Testing
- Hello for Cancer game, Table Topics game
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Milton S. Hershey Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.